Neurometrix Inc (NASDAQ:NURO) has earned an average broker rating score of 2.00 (Buy) from the two analysts that cover the company, Zacks Investment Research reports. One investment analyst has rated the stock with a hold rating and one has given a strong buy rating to the company.
Brokers have set a 12-month consensus price target of $5.00 for the company and are anticipating that the company will post ($0.19) EPS for the current quarter, according to Zacks. Zacks has also assigned Neurometrix an industry rank of 95 out of 256 based on the ratings given to its competitors.
NURO has been the subject of a number of analyst reports. ValuEngine raised Neurometrix from a “hold” rating to a “buy” rating in a research report on Monday, April 1st. HC Wainwright reaffirmed a “buy” rating and set a $5.00 price objective on shares of Neurometrix in a research report on Friday, April 26th. Finally, Zacks Investment Research raised Neurometrix from a “hold” rating to a “buy” rating and set a $1.00 price objective for the company in a research report on Saturday, April 27th.
Shares of NASDAQ:NURO traded down $0.04 during trading on Friday, hitting $0.50. The stock had a trading volume of 5,498 shares, compared to its average volume of 264,069. Neurometrix has a 12 month low of $0.48 and a 12 month high of $1.77. The firm has a market capitalization of $4.67 million, a P/E ratio of 4.18 and a beta of 0.74.
Neurometrix (NASDAQ:NURO) last announced its earnings results on Thursday, April 25th. The medical device company reported $0.15 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.15) by $0.30. Neurometrix had a return on equity of 11.77% and a net margin of 6.36%. The firm had revenue of $3.12 million during the quarter, compared to analyst estimates of $3.92 million. On average, analysts forecast that Neurometrix will post -0.35 earnings per share for the current fiscal year.
A hedge fund recently raised its stake in Neurometrix stock. Renaissance Technologies LLC boosted its stake in shares of Neurometrix Inc (NASDAQ:NURO) by 55.1% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 213,615 shares of the medical device company’s stock after purchasing an additional 75,932 shares during the period. Renaissance Technologies LLC owned about 2.90% of Neurometrix worth $284,000 at the end of the most recent quarter. 10.38% of the stock is owned by institutional investors and hedge funds.
NeuroMetrix, Inc, a healthcare company, develops and markets products for the detection, diagnosis, and monitoring of peripheral nerve and spinal cord disorders. The company develops wearable neuro-stimulation therapeutic devices and point-of-care neuropathy diagnostic tests to address chronic health conditions, including chronic pain, sleep disorders, and diabetes.
Recommended Story: Quiet Period Expirations
Get a free copy of the Zacks research report on Neurometrix (NURO)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Neurometrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurometrix and related companies with MarketBeat.com's FREE daily email newsletter.